Compare Stocks

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$5.41 -3.6%	$6.47	$2.78 ▼ $8.85	$29.38M	1.03	30,471 shs	7,280 shs
KERN Akerna		$5.89	$0.17 ▼ $6.40	$64.92M	3.02	339,022 shs	70,795 shs
NH NantHealth	$0.39 +14.8%	$0.39	$1.24 ▼ $9.75	$2.98M	1.82	38,073 shs	788 shs
VINC Vincerx Pharma	$0.85 -5.6%	$4.16	$0.61 ▼ $9.37	$18.20M	1.1	1.29 million shs	354,883 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	+1.92%	-1.02%	-13.35%	+8.35%	+43.84%
KERN Akerna	0.00%	0.00%	0.00%	+12.32%	-61.94%
NH NantHealth	0.00%	-27.68%	-38.00%	-5.28%	-79.08%
VINC Vincerx Pharma	-5.28%	-10.00%	-85.71%	-15.89%	-9.09%

Bitcoin Rockets To Record High But Buy THIS Instead (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	3.2007 of 5 stars	3.5	5.0	0.0	0.0	1.7	3.3	0.6
KERN Akerna	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NH NantHealth	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	2.2125 of 5 stars	3.5	4.0	0.0	0.0	1.7	2.5	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	186.51% Upside
KERN Akerna	N/A	N/A	N/A	N/A
NH NantHealth	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	3.00	Buy	$5.00	488.24% Upside

Current Analyst Ratings

Latest NH, KERN, VINC, and APRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	VINC Vincerx Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
4/1/2024	VINC Vincerx Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
3/27/2024	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$9.00 ➝ $11.00
3/26/2024	APRE Aprea Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$580K	50.65	N/A	N/A	$4.54 per share	1.19
KERN Akerna	$13.65M	0.00	N/A	N/A	($1.52) per share	0.00
NH NantHealth	$67.68M	0.04	N/A	N/A	($30.72) per share	-0.01
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$14.29M	-$3.99	N/A	N/A	N/A	N/A	-65.58%	-52.37%	5/20/2024 (Estimated)
KERN Akerna	-$79.06M	-$7.10	N/A	N/A	N/A	-339.99%	N/A	-113.03%	N/A
NH NantHealth	-$67.78M	-$7.65	N/A	∞	N/A	-94.67%	N/A	-39.82%	N/A
VINC Vincerx Pharma	-$40.16M	-$1.89	N/A	N/A	N/A	N/A	-187.73%	-126.26%	5/9/2024 (Estimated)

Latest NH, KERN, VINC, and APRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	APRE Aprea Therapeutics	-$0.56	-$0.92	-$0.36	-$0.92	$0.33 million	$0.01 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
KERN Akerna	N/A	N/A	N/A	N/A	N/A
NH NantHealth	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.13	5.13
KERN Akerna	N/A	0.10	0.10
NH NantHealth	N/A	0.64	0.64
VINC Vincerx Pharma	N/A	2.63	2.63

Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
KERN Akerna	21.97%
NH NantHealth	4.50%
VINC Vincerx Pharma	44.02%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	20.90%
KERN Akerna	1.20%
NH NantHealth	61.30%
VINC Vincerx Pharma	20.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	9	5.43 million	4.30 million	No Data
KERN Akerna	112	10.35 million	10.23 million	No Data
NH NantHealth	326	7.70 million	2.98 million	Not Optionable
VINC Vincerx Pharma	41	21.41 million	17.00 million	Not Optionable

NH, KERN, VINC, and APRE Headlines

Source	Headline
	AACR: Biotechs emerge frostbitten from ‘nuclear winter,’ ready to show why they fought for survival fiercebiotech.com - April 18 at 12:36 PM
	Analyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC) americanbankingnews.com - April 16 at 2:40 AM
	Agendia’s BluePrint Included in German Oncology Group Guidelines finance.yahoo.com - April 12 at 9:45 AM
	Vaccines, Next-Gen Approaches Target the Toughest Cancers: AACR biospace.com - April 12 at 9:45 AM
	The Rise of Zyn: The Oral Nicotine Product Going Viral finance.yahoo.com - April 10 at 4:08 PM
	Vincerx Pharma Inc (VINC) Gets a Buy from Leerink Partners markets.businessinsider.com - April 10 at 9:44 AM
	Vincerx Pharma's (VINC) "Overweight" Rating Reaffirmed at Cantor Fitzgerald americanbankingnews.com - April 10 at 4:14 AM
	Vincerx (VINC) Tumbles on Results From Cancer Therapy Study zacks.com - April 9 at 2:36 PM
	ACOR, HUBC and DATS among pre-market losers msn.com - April 9 at 9:19 AM
	Vincerx in selloff after early-stage data for cancer therapy msn.com - April 9 at 9:19 AM
	Cantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC) marketbeat.com - April 9 at 8:49 AM
	Why Is Vincerx Pharma (VINC) Stock Down 64% Today? investorplace.com - April 9 at 8:40 AM
	Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 globenewswire.com - April 8 at 4:30 PM
	FY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC) marketbeat.com - April 4 at 9:13 AM
	Q1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink Partnrs marketbeat.com - April 3 at 6:00 AM
	VINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023 investorplace.com - April 2 at 8:06 AM
	Vincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update finanznachrichten.de - April 1 at 4:30 PM
	Vincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor Fitzgerald marketbeat.com - April 1 at 12:23 PM
	Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 finance.yahoo.com - April 1 at 10:47 AM
	Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look finance.yahoo.com - March 29 at 8:49 PM
	Vincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024 marketwatch.com - March 29 at 3:48 PM
	Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update globenewswire.com - March 29 at 3:20 PM
	Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2% marketbeat.com - March 28 at 8:34 AM
	Vincerx Pharma (VINC) Set to Announce Earnings on Tuesday marketbeat.com - March 25 at 7:31 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
Intuitive Machines: Charting a Course Among the Stars
March 21, 2024 11:30 AM
View Intuitive Machines: Charting a Course Among the Stars
Undervalued UnitedHealth Group Won’t Be For Long
April 16, 2024 10:53 AM
View Undervalued UnitedHealth Group Won’t Be For Long
Robinhood’s Credit Card Has Call Option Buyers Coming in Hot
April 3, 2024 8:45 AM
View Robinhood’s Credit Card Has Call Option Buyers Coming in Hot

All Headlines

Company Descriptions

Aprea Therapeutics

NASDAQ:APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Akerna

NASDAQ:KERN

Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.

NantHealth

NASDAQ:NH

NantHealth, Inc. engages in the provision of enterprise solutions that help businesses transform complex data into actionable insights. It is also involved in marketing solutions as a comprehensive integrated solution that includes clinical decision support, payer engagement solutions, data analysis, and network monitoring and management. The company was founded by Patrick Soon-Shiong on July 7, 2010 and is headquartered in Morrisville, NC.

Vincerx Pharma

NASDAQ:VINC

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial